Open AccessSingle-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
Author(s) -
James N. Ingle,
Krishna R. Kalari,
Poulami Barman,
Lois E. Shepherd,
Matthew J. Ellis,
Paul E. Goss,
Aman U. Buzdar,
Mark E. Robson,
Junmei Cairns,
Erin E. Carlson,
Abraham Eyman Casey,
Tanya L. Hoskin,
Barbara Goodnature,
Tufia C. Haddad,
Matthew P. Goetz,
Richard M. Weinshilboum,
Liewei Wang
Publication year - 2020
Publication title -
pharmacogenetics and genomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.579
H-Index - 140
eISSN - 1744-6880
pISSN - 1744-6872
DOI - 10.1097/fpc.0000000000000415
Subject(s) - anastrozole , single nucleotide polymorphism , oncology , medicine , breast cancer , cohort , snp , genotyping , tamoxifen , genotype , cancer , biology , genetics , gene
Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/ml and 0.5 pg/ml, respectively, after 6 months of adjuvant anastrozole therapy had a three-fold risk of recurrence, we aimed to identify a single-nucleotide polymorphism (SNP)-based model that would predict elevated E1 and E2 and then validate it in an independent dataset.